Volume 26, Issue 11 , Pages 1456-1462, November 2010
The Effect of Recombinant Human Platelet-Derived Growth Factor BB–Coated Sutures on Rotator Cuff Healing in a Sheep Model
Purpose
The purpose of this study was to determine whether suture could be coated with recombinant human platelet-derived growth factor BB (rhPDGF-BB) and whether the coated suture would improve histologic scores and biomechanical strength of sheep rotator cuff repairs.
Methods
FiberWire sutures (Arthrex, Naples, FL) were dip coated in a collagen–rhPDGF-BB solution. Coating was confirmed by use of enzyme-linked immunosorbent assay. Rotator cuff tears were created in 18 sheep. The tendons were wrapped in Gortex (Gore Medical, Flagstaff, AZ) and allowed to scar for 2 weeks. Tendons were then repaired to bone by use of standard anchors loaded with either rhPDGF-BB–coated sutures or uncoated sutures. Gross examination, histologic analysis, and biomechanical testing were performed 6 weeks after repair.
Results
Enzyme-linked immunosorbent assay confirmed successful loading of the growth factor onto the sutures. Gross examination showed well-healed tendon-to-bone interfaces in both rhPDGF-BB–augmented repairs and controls. Histologic analysis using a semiquantitative rating scale showed improved tendon-to-bone healing in the rhPDGF-BB–augmented repairs. There was no significant difference in the ultimate load to failure of rhPDGF-BB–augmented rotator cuff repairs compared with standard suture repairs at 6 weeks after repair.
Conclusions
We were able to coat No. 2 FiberWire with rhPDGF-BB. At short-term follow-up, rhPDGF-BB–coated sutures enhanced histologic scores of sheep rotator cuff repairs; however, ultimate load to failure was equivalent to standard suture repairs.
Clinical Relevance
rhPDGF-BB–coated sutures seem to produce a more histologically normal tendon insertion.
To access this article, please choose from the options below
Supported by a grant from The Oxnard Foundation, Oxnard, California. J.D. currently works as a consultant with BioMimetic Therapeutics, Franklin, Tennessee, the manufacturer of recombinant human platelet-derived growth factor BB. The other authors report no conflict of interest.
PII: S0749-8063(10)00194-5
doi:10.1016/j.arthro.2010.02.025
© 2010 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.
Volume 26, Issue 11 , Pages 1456-1462, November 2010


